SensoDetect accelerates international autism study and expands data collection to fuel next-generation algorithms

Strategic moves in the Middle East and globally aim to de-risk clinical program and enhance the value of proprietary neuropsychiatric diagnostic technology.

Sensodetect AB (publ) today announced a series of strategic initiatives to accelerate its clinical validation program and strengthen the foundation for its AI-driven diagnostic platform. The company is intensifying efforts on its landmark autism spectrum disorder (ASD) study in Saudi Arabia while simultaneously launching broader data collection projects to train its next-generation software.

A key step involves reinforcing the company's presence in the Middle East. To optimize the execution of the Saudi Arabian autism study, Dr. Atwa, Head of Clinical Research, has relocated to Sweden to enhance direct collaboration with the research and development team. This move is complemented by an upcoming visit of CEO, P-A Hedin, to Dubai in early October to engage with regional partners and clinical sites.

"From a clinical perspective, having Dr. Atwa integrated with our core R&D team in Sweden will streamline data analysis and protocol refinement, which is crucial for a high-quality study," said P-A Hedin, CEO of Sensodetect. "From a strategic viewpoint, my visit to the region underscores the immense market potential we see in the Middle East for our tools. We are tackling the study's operational challenges head-on to drive enrollment and generate the robust data set we need."

In parallel, Sensodetect is initiating multiple projects to significantly expand its dataset of neurophysiological data. This large-scale data collection, targeting diverse populations across China, the Middle East, and Europe, is not merely for validation but is fundamental to training more advanced and accurate machine learning algorithms.

This expanded and diverse dataset is a critical corporate asset. It is expected to enhance the algorithm's performance, directly supporting the company's strategy to develop scalable, precise, and clinically valuable diagnostic tools for global neuropsychiatric markets. A larger and more robust dataset also strengthens the company's position for future regulatory submissions.

Sensodetect remains committed to establishing itself as a global leader in medical technology, with a dedicated focus on innovative, objective solutions for neuropsychiatric screening and diagnostics.

For more information or partnership inquiries, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)46 15 79 04

pa.hedin@sensodetect.com

SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of screening, diagnostics, medication, and health. The products are used in both private and public healthcare and schools, as a screening and complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.

More info at https://www.sensodetect.com/

https://news.cision.com/se/sensodetect-ab/r/sensodetect-accelerates-international-autism-study-and-expands-data-collection-to-fuel-next-generati%2Cc4238287